Great Lakes Advisors LLC Lowers Holdings in Becton, Dickinson and Company $BDX

Great Lakes Advisors LLC lowered its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 14.8% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 206,911 shares of the medical instruments supplier’s stock after selling 35,818 shares during the quarter. Great Lakes Advisors LLC’s holdings in Becton, Dickinson and Company were worth $31,312,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Brighton Jones LLC grew its holdings in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Becton, Dickinson and Company by 4.4% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 627,900 shares of the medical instruments supplier’s stock valued at $122,403,000 after acquiring an additional 26,671 shares during the period. Cooke & Bieler LP lifted its holdings in Becton, Dickinson and Company by 27.2% in the fourth quarter. Cooke & Bieler LP now owns 1,126,471 shares of the medical instruments supplier’s stock valued at $218,614,000 after acquiring an additional 240,673 shares during the period. KLP Kapitalforvaltning AS boosted its position in shares of Becton, Dickinson and Company by 61.2% during the 4th quarter. KLP Kapitalforvaltning AS now owns 172,580 shares of the medical instruments supplier’s stock worth $33,493,000 after purchasing an additional 65,500 shares in the last quarter. Finally, Northside Capital Management LLC grew its stake in shares of Becton, Dickinson and Company by 18.3% during the 2nd quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier’s stock worth $9,280,000 after purchasing an additional 9,494 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $181.17 on Wednesday. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35. The stock has a market cap of $49.92 billion, a P/E ratio of 54.57, a PEG ratio of 12.93 and a beta of 0.19. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The company has a 50-day moving average of $159.06 and a two-hundred day moving average of $161.12.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same period last year, the company posted $3.68 EPS. The company’s revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, research analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 annualized dividend and a yield of 2.3%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 126.51%.

Analysts Set New Price Targets

Several brokerages recently commented on BDX. Jefferies Financial Group reiterated a “buy” rating and issued a $210.00 price objective on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Barclays upped their target price on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Evercore set a $180.00 price target on shares of Becton, Dickinson and Company in a research report on Monday, July 6th. Royal Bank Of Canada boosted their price target on Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a research note on Thursday, August 13th. Finally, TD Cowen upped their price target on Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. Eight investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company has an average rating of “Hold” and a consensus target price of $185.67.

Insider Transactions at Becton, Dickinson and Company

In other news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the company’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the sale, the chief executive officer directly owned 110,163 shares in the company, valued at $20,380,155. This represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the sale, the executive vice president directly owned 13,172 shares in the company, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 11,779 shares of company stock valued at $1,974,669 over the last three months. 0.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.